Simple Summary In 2017, two chimeric antigen receptor-T (CAR-T) therapies were
approved by the FDA for advanced/resistant lymphoma and acute lymphoblastic leukemia …

Chimeric antigen receptor T (CAR-T) cell therapy achieved extraordinary achievements
results in antitumor treatments, especially against hematological malignancies, where it …

Despite the ups and downs in the field over three decades, the science of gene therapy has
continued to advance and provide enduring treatments for increasing number of diseases …

Pancreatic cancer is an aggressive disease that is predicted to become the second leading
cause of cancer-related death worldwide by 2030. The overall 5-year survival rate is around …

Advancements in chimeric antigen receptor engineered T-cell (CAR-T) therapy have
revolutionized treatment for several cancer types over the past decade. Despite this success …

Allogeneic Vγ9Vδ2 (Vδ2) T cells have emerged as attractive candidates for developing
cancer therapy due to their established safety in allogeneic contexts and inherent tumor …

Immunotherapy has become a promising research “hotspot” in cancer treatment.“Soldier”
immune cells are not uniform throughout the body; they accumulate mostly in the immune …

Today, cancer treatment is one of the fundamental problems facing clinicians and
researchers worldwide. Efforts to find an excellent way to treat this illness continue, and new …

This study aimed to characterize different natural killer (NK) cell phenotypes on bone
marrow and peripheral blood cells from acute myeloid leukemia (AML) patients and healthy …

Cancer is becoming increasingly understood not only as a disease of pathological cells but
also as one of immune hypofunction. The heterogenous and patient-specific nature of …